Treace Medical Concepts, Inc. Common Stock (TMCI) Stock
NASDAQ · TMCI
Key stats
- Market cap
- $278.35M
- Price / Earnings ratio
- -4.5x
- EPS (TTM)
- -$0.72
- Volume
- Loading
- 52-week high
- $7.08
- 52-week low
- $1.17
Source: third-party data provider, as of October 24, 2026
Compare with TMCI
Recent news

MarketBeat
Treace Medical Concepts Q2 Earnings Call Highlights
TMCIAugust 7, 2026
MarketBeat
Treace Medical Concepts Q2 Earnings Call Highlights
TMCI

Zacks Investment Research
Treace Medical Concepts (TMCI) Reports Q2 Loss, Tops Revenue Estimates
TMCIAugust 7, 2026
Zacks Investment Research
Treace Medical Concepts (TMCI) Reports Q2 Loss, Tops Revenue Estimates
TMCI

MarketBeat
Treace Medical Concepts Q1 Earnings Call Highlights
TMCIMay 9, 2026
MarketBeat
Treace Medical Concepts Q1 Earnings Call Highlights
TMCI

Zacks Investment Research
Treace Medical Concepts (TMCI) Reports Q1 Loss, Beats Revenue Estimates
TMCIMay 8, 2026
Zacks Investment Research
Treace Medical Concepts (TMCI) Reports Q1 Loss, Beats Revenue Estimates
TMCI
Technical indicators
- RSI 14
- 52.04
- MACD 12/26/9
- -0.10
- EMA 9 of MACD
- -0.12
- MACD histogram
- 0.02
- SMA 50
- $4.42
- Price below SMA 50
- EMA 50
- $4.27
- Price above EMA 50
- SMA 200
- $3.18
- Price above SMA 200
- EMA 200
- $3.54
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 22, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 1 analyst rating
Strong Sell0
Sell0
Hold1
Buy0
Strong Buy0
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Revenue
Net income
Net margin %
2025
255M168M84M0
Debt & Balance Sheet
Total assets
Total liabilities
2025
229M151M75M0
Revenue to Profit
2025$212.7M
Revenue$0.0
Cost of revenue$169.8M
Gross profit$0.0
Operating expenses$-59.0M
Net incomeEarnings
No data available
Source: third-party data provider
Latest news

MarketBeat
Treace Medical Concepts Q2 Earnings Call Highlights
TMCIAugust 7, 2026
MarketBeat
Treace Medical Concepts Q2 Earnings Call Highlights
TMCI

Zacks Investment Research
Treace Medical Concepts (TMCI) Reports Q2 Loss, Tops Revenue Estimates
TMCIAugust 7, 2026
Zacks Investment Research
Treace Medical Concepts (TMCI) Reports Q2 Loss, Tops Revenue Estimates
TMCI

MarketBeat
Treace Medical Concepts Q1 Earnings Call Highlights
TMCIMay 9, 2026
MarketBeat
Treace Medical Concepts Q1 Earnings Call Highlights
TMCI

Zacks Investment Research
Treace Medical Concepts (TMCI) Reports Q1 Loss, Beats Revenue Estimates
TMCIMay 8, 2026
Zacks Investment Research
Treace Medical Concepts (TMCI) Reports Q1 Loss, Beats Revenue Estimates
TMCI

Benzinga
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month - Renovaro (NASDAQ:RENB)
TMCIMay 21, 2024
Benzinga
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month - Renovaro (NASDAQ:RENB)
TMCI

24/7 Wall Street
CEOs and Other Insiders Are Buying Shares of These 7 Stocks
TMCIMay 19, 2024
24/7 Wall Street
CEOs and Other Insiders Are Buying Shares of These 7 Stocks
TMCI

InvestorPlace
7 Stable Stocks for 50% Returns by Early 2025
TMCIApril 15, 2024
InvestorPlace
7 Stable Stocks for 50% Returns by Early 2025
TMCI
About Treace Medical Concepts, Inc. Common Stock
No description available.
SectorHealthcare
IndustryMedical Devices
Employees450
CEOMr. John T. Treace
IPO DateApr 22, 2021
HeadquartersPonte Vedra, FL
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. John T. Treace | Founder, Chairman & CEO | 1972 |
| Mr. Mark L. Hair CPA | Chief Financial Officer | 1970 |
| Mr. Scot M. Elder J.D. | Chief Legal & Compliance Officer and Corporate Secretary | 1975 |
| Dr. Sean F. Scanlan Ph.D. | Chief Innovation & Marketing Officer | 1982 |
| Mr. Terry W. Lubben | Chief Operations & Supply Chain Officer | 1965 |
| Mr. Zac Potter | Senior VP & Chief Accounting Officer | — |
| Mr. Taylor Erickson | Chief Information & Cybersecurity Officer | — |
| Mr. Brad Barr | Senior Vice President of Sales | — |
| Mr. Daniel E. Owens | Chief Human Resources Officer | 1972 |
| Ms. Shana Zink | Senior Vice President of Clinical Affairs & Reimbursement | — |
Fundamentals
Valuation
Price-to-sales ratio1.29
Price-to-book value3.97
Profitability
Return on Equity-74.00%
Return on Assets-32.00%
Return on Sales-26.00%
Gross margin (latest quarter)78.47%
EBITDA$-43.13M
Trading
Average volume216,505
Source: third-party data provider, as of October 24, 2026
Technical indicators
- RSI 14
- 52.04
- MACD 12/26/9
- -0.10
- EMA 9 of MACD
- -0.12
- MACD histogram
- 0.02
- SMA 50
- $4.42
- Price below SMA 50
- EMA 50
- $4.27
- Price above EMA 50
- SMA 200
- $3.18
- Price above SMA 200
- EMA 200
- $3.54
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 22, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
Analyst consensus:Hold
0% Buy
100% Hold
0% Sell
Analyst price target
- Low
- $5.00
- Average
- $5.00
- High
- $5.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +4.2 | -26.5 | +3.8 | |||||||||
| 2022 | -8.2 | +15.9 | -10.1 | +0.5 | -14.8 | -13.7 | +15.0 | +17.6 | +11.9 | +7.2 | -1.3 | -6.8 |
| 2023 | +3.1 | -8.7 | +19.7 | -5.5 | +2.2 | -3.5 | -6.9 | -29.1 | -15.8 | -19.7 | -13.3 | +36.9 |
| 2024 | +7.3 | -5.3 | -2.8 | -17.0 | -45.9 | +21.4 | +11.4 | -6.4 | +1.4 | -13.9 | +78.2 | -15.3 |
| 2025 | +27.7 | -7.7 | -4.2 | -13.1 | -21.8 | +2.4 | -10.8 | +37.5 | -6.4 | +1.1 | -54.8 | -13.4 |
| 2026 | -7.2 | -17.7 | -19.3 | +28.4 | +86.0 | +10.6 | +1.9 | +0.4 | -3.5 | -1.2 |
Compare stocks
Market cap
$278.35M
-
-
-
Price / Earnings ratio
-4.50
-
-
-
Price / Sales ratio
1.29
-
-
-
Dividend yield
0.00%
-
-
-
Average volume
216,505
-
-
-
Earnings per share
$-0.72
-
-
-



